Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine

This study assessed response rates to combination dacarbazine (DTIC), BCNU (carmustine), cisplatin and tamoxifen (DBPT) chemotherapy in patients with progressive metastatic melanoma previously treated with DTIC, as an evaluation of DBPT as a second-line regimen, and as an indirect comparison of DBPT...

Descripción completa

Detalles Bibliográficos
Autores principales: Propper, D J, Braybrooke, J P, Levitt, N C, O'Byrne, K, Christodoulos, K, Han, C, Talbot, D C, Ganesan, T S, Harris, A L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363219/
https://www.ncbi.nlm.nih.gov/pubmed/10839287
http://dx.doi.org/10.1054/bjoc.2000.1141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363219/
https://www.ncbi.nlm.nih.gov/pubmed/10839287
http://dx.doi.org/10.1054/bjoc.2000.1141

Ejemplares similares